Citadel Advisors
ICPT

Citadel Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Citadel Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-172,600
Closed -$3.2M – 15659
2023
Q3 		$3.2M Sell
172,600
-13,300
-7% -$150K ﹤0.01% 4369
2023
Q2 		$2.06M Buy
185,900
+74,100
+66% +$1.03M ﹤0.01% 5103
2023
Q1 		$1.5M Sell
111,800
-55,300
-33% -$957K ﹤0.01% 5909
2022
Q4 		$2.07M Sell
167,100
-169,000
-50% -$2.39M ﹤0.01% 5421
2022
Q3 		$4.69M Buy
336,100
+182,400
+119% +$2.94M ﹤0.01% 3986
2022
Q2 		$2.12M Sell
153,700
-7,900
-5% -$126K ﹤0.01% 5416
2022
Q1 		$2.63M Sell
161,600
-41,400
-20% -$648K ﹤0.01% 5474
2021
Q4 		$3.31M Buy
203,000
+13,600
+7% +$229K ﹤0.01% 5143
2021
Q3 		$2.81M Buy
189,400
+80,100
+73% +$1.28M ﹤0.01% 5523
2021
Q2 		$2.18M Buy
109,300
+1,600
+1% +$31.7K ﹤0.01% 6378
2021
Q1 		$2.49M Sell
107,700
-47,300
-31% -$1.32M ﹤0.01% 5889
2020
Q4 		$3.83M Buy
155,000
+36,900
+31% +$1.22M ﹤0.01% 4154
2020
Q3 		$4.9M Sell
118,100
-48,500
-29% -$2.23M ﹤0.01% 3190
2020
Q2 		$7.98M Buy
166,600
+42,600
+34% +$3.29M ﹤0.01% 2492
2020
Q1 		$7.81M Sell
124,000
-160,600
-56% -$14.4M ﹤0.01% 2146
2019
Q4 		$35.3M Buy
284,600
+100,200
+54% +$8.97M 0.02% 1004
2019
Q3 		$12.2M Buy
184,400
+152,700
+482% +$10.3M 0.01% 1987
2019
Q2 		$2.52M Sell
31,700
-240,500
-88% -$21.5M ﹤0.01% 4130
2019
Q1 		$30.4M Buy
272,200
+109,700
+68% +$12M 0.02% 1012
2018
Q4 		$16.4M Buy
162,500
+3,100
+2% +$321K 0.01% 1399
2018
Q3 		$20.1M Buy
159,400
+87,400
+121% +$9.25M 0.01% 1388
2018
Q2 		$6.04M Buy
72,000
+57,400
+393% +$4.2M ﹤0.01% 2519
2018
Q1 		$898K Sell
14,600
-83,600
-85% -$5.04M ﹤0.01% 4984
2017
Q4 		$5.74M Sell
98,200
-26,100
-21% -$1.65M ﹤0.01% 2326
2017
Q3 		$7.21M Buy
124,300
+101,400
+443% +$10.9M 0.01% 1915
2017
Q2 		$2.77M Buy
22,900
+5,900
+35% +$683K ﹤0.01% 2754
2017
Q1 		$1.92M Sell
17,000
-31,100
-65% -$3.63M ﹤0.01% 3121
2016
Q4 		$5.23M Buy
48,100
+2,200
+5% +$262K 0.01% 1954
2016
Q3 		$7.55M Sell
45,900
-14,500
-24% -$2.29M 0.01% 1608
2016
Q2 		$8.62M Sell
60,400
-6,200
-9% -$904K 0.01% 1358
2016
Q1 		$8.56M Buy
66,600
+37,000
+125% +$4.37M 0.01% 1322
2015
Q4 		$4.42M Buy
29,600
+2,700
+10% +$457K ﹤0.01% 1923
2015
Q3 		$4.46M Buy
26,900
+1,800
+7% +$396K ﹤0.01% 2064
2015
Q2 		$6.06M Sell
25,100
-27,900
-53% -$7.43M 0.01% 1887
2015
Q1 		$14.9M Buy
53,000
+19,400
+58% +$4.2M 0.01% 1156
2014
Q4 		$5.24M Buy
33,600
+4,100
+14% +$757K 0.01% 1937
2014
Q3 		$6.98M Buy
29,500
+4,400
+18% +$1.12M 0.01% 1680
2014
Q2 		$5.94M Sell
25,100
-2,200
-8% -$580K 0.01% 1686
2014
Q1 		$9M Buy
+27,300
New +$9.21M 0.01% 1342

Citadel Advisors's ICPT Position: Q4 2023 in Review

Citadel Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 81,972 shares — an estimated $1.52M sold.

Citadel Advisors first reported a position in ICPT in Q1 2014 and held it in 37 quarters. The position peaked at $84.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Citadel Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 81,972 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.52M.
  • Citadel Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 37 quarters.
  • Citadel Advisors's Intercept Pharmaceuticals, Inc. position peaked at $84.3M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.